HWM
GBT

HighMark Wealth Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

HighMark Wealth Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-63
Closed -$3K – 491
2020
Q3 		$3K Sell
63
-112
-64% -$7.12K ﹤0.01% 383
2020
Q2 		$11K Buy
+175
New +$12K 0.01% 188

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

HighMark Wealth Management's GBT Position: Q4 2020 in Review

HighMark Wealth Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 63 shares — an estimated $3K sold.

HighMark Wealth Management first reported a position in GBT in Q2 2020 and held it in 2 quarters. The position peaked at $11K in Q2 2020. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

  • HighMark Wealth Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • HighMark Wealth Management sold 63 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $3K.
  • HighMark Wealth Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2020 and held it in 2 quarters.
  • HighMark Wealth Management's Global Blood Therapeutics, Inc. position peaked at $11K in Q2 2020.
  • 228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on HighMark Wealth Management's 13F filing for Q4 2020, filed 27 Jan 2021.